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AdipokineIntroduction: Liver ﬁbrosis develops when hepatic stellate cells (HSC) are activated into collagen-producing
myoﬁbroblasts. In non-alcoholic steatohepatitis (NASH), the adipokine leptin is upregulated, and promotes
liver ﬁbrosis by directly activating HSC via the hedgehog pathway. We reported that hedgehog-regulated
osteopontin (OPN) plays a key role in promoting liver ﬁbrosis. Herein, we evaluated if OPN mediates leptin-
proﬁbrogenic effects in NASH.
Methods: Leptin-deﬁcient (ob/ob) and wild-type (WT) mice were fed control or methionine-choline deﬁcient
(MCD) diet. Liver tissues were assessed by Sirius-red, OPN and αSMA IHC, and qRT-PCR for ﬁbrogenic genes.
In vitro, HSC with stable OPN (or control) knockdown were treated with recombinant (r)leptin and OPN-
neutralizing or sham-aptamers. HSC response to OPN loss was assessed by wound healing assay. OPN-
aptamers were also added to precision-cut liver slices (PCLS), and administered to MCD-fed WT (leptin-intact)
mice to determine if OPN neutralization abrogated ﬁbrogenesis.
Results: MCD-fed WT mice developed NASH-ﬁbrosis, upregulated OPN, and accumulated αSMA+ cells.
Conversely, MCD-fed ob/ob mice developed less ﬁbrosis and accumulated fewer αSMA+ and OPN+ cells. In
vitro, leptin-treated HSC upregulated OPN, αSMA, collagen 1α1 and TGFβmRNA by nearly 3-fold, but this effect
was blunted by OPN loss. Inhibition of PI3K and transduction of dominant negative-Akt abrogated leptin-
mediated OPN induction, while constitutive active-Akt upregulated OPN. Finally, OPN neutralization reduced
leptin-mediated ﬁbrogenesis in both PCLS and MCD-fed mice.
Conclusion: OPN overexpression in NASH enhances leptin-mediated ﬁbrogenesis via PI3K/Akt. OPN neutraliza-
tion signiﬁcantly reduces NASH ﬁbrosis, reinforcing the potential utility of targeting OPN in the treatment of
patients with advanced NASH.
© Elsevier B.V. All rights reserved.2015e; OPN, osteopontin; TGF-β, transforming growth factor β; αSMA, alpha smooth muscle actin; MCD diet, methionine choline
PF, high-powered ﬁeld; shScr, short-hairpin RNA against non-target (scrambled) sequence; shOPN, short-hairpin RNA against
, Foundation for Liver Research, London WC1E 6HX, UK.
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Individuals with nonalcoholic steatohepatitis (NASH), an advanced
stage of nonalcoholic fatty liver disease (NAFLD), are at risk of disease
progression that leads to liver ﬁbrosis, cirrhosis, and cancer [1–4]. The
mechanisms which drive NASH progression are not entirely under-
stood, but studies suggest that liver cell injury from lipotoxicity and
oxidative stress triggers a ﬁbrogenic repair response. Liver ﬁbrosis de-
velops when this injury-associated repair response becomes excessive
or deregulated [5–6].
The hepatic stellate cell (HSC) or liver pericyte is the major source
of extracellular matrix, and thus, the key effector of the repair response
[7]. When activated by cytokines (transforming growth factor β),
growth factors (connective tissue growth factor), or morphogens
(hedgehog (Hh), Wnt), quiescent HSC transition into motile, collagen-
secreting myoﬁbroblasts [8]. HSCs are also capable of responding to
circulating neurotransmitters and hormones [9,10]. Leptin is an
adipocyte-derived hormone which, not only controls energy balance
and food in-take, but also modulates the liver repair response [11–13].
Binding of leptin to HSC surface receptors for instance, upregulates
key ﬁbrogenic genes αSMA and collagen 1α1, while mice deﬁcient in
leptin (i.e. ob/ob mice) are protected against liver ﬁbrosis [11,14,15].
In humans, serum and tissue leptin levels are highly elevated in the
obese [16–18], helping to explain at least in part, why obese, NAFLD
individuals are more at risk of developing liver ﬁbrosis.
Recently, we reported that leptin-induced liver ﬁbrosis occurs via
activation of the Hh pathway [19] (a key morphogenic signal that regu-
lates development as well as adult tissue inﬂammation and ﬁbrosis),
and that upregulation of the Hh ligand and downstream target genes
requires induction of the PI3K/Akt signaling. Hh pathway activation
promotes transition of quiescent HSC into activated myoﬁbroblasts
[20], while inhibition of Hh reverses this phenotype. Similarly, the
addition of LY294002 (a PI3K inhibitor) or cyclopamine (a speciﬁc Hh
pathway inhibitor) to leptin-treated HSC blocked all actions of leptin,
thus revealing that the PI3K–Hh axis is necessary for leptin to exert its
ﬁbrogenic effects.
Osteopontin (OPN) is a pro-inﬂammatory cytokine and matrix
protein that is highly expressed in a variety of inﬂamed tissues, and
plays a critical role in tissue repair [21,22]. OPN levels are upregulated
in tissue and blood of patients with chronic liver disease, and have
been shown to activate liver progenitors and HSC [23]; functionally
resembling Hh. Interestingly, mice with excessive Hh pathway activity
express more liver OPN and develop worse liver ﬁbrosis, while inhibi-
tion of Hh signaling (with cyclopamine) in HSC represses OPN levels
[24]. These results demonstrate that OPN is a downstream effector of
Hh, and led us to hypothesize that OPN and leptin may interact in HSC
to promote NASH progression.
Using a combination of HSC cultures and diet-induced model of
NASH, we conﬁrm that OPN is a downstream effector of leptin, and is
required for ﬁbrotic outcomes in NASH. These results are clinically im-
portant because humanized antibodies and aptamers which inhibit
OPN actions have been developed, and may be used to treat patients
with advanced NASH.2. Methods
2.1. Mice
Lean (WT) and obese (ob/ob) mice (males, C57BL/6 background)
were obtained from Jackson Laboratories (Bar Harbor, ME). To induce
liver injury and ﬁbrosis, ob/ob and WT mice (n = 5/group) were fed
methionine choline-deﬁcient (MCD) diets (MP Biomedicals, Solon,
OH) for a total of 8 weeks. In the control arm, ob/ob and WT mice
(n = 5/group) were permitted ad libitum consumption of water and
control chow (MP Biomedicals, Solon, OH) [23,24].In a separate study, WT mice were fed the MCD diet for 6 weeks.
Sham-aptamers or OPN-speciﬁc aptamers (see below) were adminis-
tered from week 4, via daily tail-vein injection (200 μg/injection/
mouse) [25,26].
At the end of treatments, mice were sacriﬁced and livers harvested
for qRTPCR and immunohistochemistry. Animal care and procedures
were as per theNIH “Guide for the Care and Use of Laboratory Animals”,
and approved by relevant institutions: Duke University Institutional
Animal Care and Use Committees, and the University of Calgary Animal
Care Committee.
2.2. Immunohistochemistry
Liver tissue was ﬁxed in formalin and embedded in parafﬁn. To
quantify liver ﬁbrosis,ﬁvemicron sectionswere stainedwith picrosirius
red (Sigma, St. Louis,MO) and counterstainedwith fast green (Sigma, St.
Louis, MO). Immunohistochemical staining to detect OPN and αSMA
was performed using the DAKO Envision System (DAKO Corporation)
according to the manufacturer's protocol. Immunostaining was
performed as previously described [23]. Antigen retrieval was per-
formed by heating in 10 mM sodium citrate buffer (pH 6.0) or incubat-
ing with pepsin (00-3009; Invitrogen). Primary antibodies used were:
anti-OPN (R&D; AF808) and anti-αSMA (Abcam; ab32575). Double
immunohistochemistry was performed using Vina Green, according to
the manufacturer's recommendation (Bio-Care Medical). Negative
controls included liver specimens exposed to 1% bovine serum albumin
instead of the respective primary antibodies. The proportion of tissue
stained with picrosirius red (Sirius-Red) content, αSMA, and OPN
were assessed bymorphometric analysiswithMetaView software (Uni-
versal Imaging Corp, Downtownington, PA) as previously described
[23]. For morphometric quantiﬁcation, 50 randomly chosen, 20× ﬁelds
per section were evaluated for each mouse.
2.3. Rat HSC isolation
Primary HSCs were isolated from Sprague–Dawley rats, assessed for
purity and viability, and seeded at a density of 3 × 102 cells/mm2 in
DMEM supplemented with 10% fetal bovine serum (FBS) and penicillin
(50 U/ml)/streptomycin (50 μg/ml) [20]. For studies that involved treat-
ments with leptin (100 ng/ml; R&D systems, Minneapolis, MN) and/or
adenoviral vectors, day 7 HSC cultures were cultured overnight in
serum-depleted medium (0.1% FBS) before treatments were initiated.
2.4. Adenoviral transduction of primary rat HSC
Ad5GFP,which contains theGFP genedriven by the cytomegalovirus
promoter, was used as a control virus. The Ad5dnAkt and Ad5myrAkt
viruses express the dominant negative and activated forms of Akt, re-
spectively [19]. Pilot studies demonstrated that maximally efﬁcient
transduction occurred at a multiplicity of infection of 100. Subsequent
experiments were carried out with this multiplicity of infection for
24 h; virus-containing medium was then aspirated and replaced with
fresh medium.
2.5. HSC line and treatments
Themouse HSC line (GRX)wasmaintained in DMEM, 5% FBS, and 1%
penicillin/streptomycin as described [27]. Cells were treated with
recombinant leptin (100 ng/ml; R&D systems, Minneapolis, MN) for
48 h. For neutralization of OPN, 40% conﬂuent cells were treated with
OPN-speciﬁc aptamers or biologically-inactive mutant sham aptamers
(6.66 μg/ml). For PI3K inhibition, LY294002 (25 μM; Cell Signalling
Technology, Danvers, MA) was applied to cells 30 min prior to treat-
ment. AG490 (50 μM; Tocris Biosciences, Ellisville, MO) was used to
inhibit JAK signaling [19].
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GRX were seeded in 24-well plates, 5 × 104 per well, serum-
starved (0.1% FBS/DMEM), and treated with 5 μg/ml polybrene
(Santa Cruz, Dallas TX) in low-serum media (0.1% FBS/DMEM) 24 h
prior to infection. Cells were trypsinized and suspended in 250 μl
media, and treatedwith 4 μl lentiviral particles (2 × 104 IFU) contain-
ing shRNA constructs speciﬁcally targeting OPN (Santa Cruz sc-
36130-V) or non-targeting scrambled control shRNA (Santa Cruz
sc-108080). The plates containing cell and viral particle suspensions
were immediately centrifuged at 750 ×g for 30 min at 25 °C,
and placed in the incubator for 48 h. After the infection period,
cells were then split, allowed to recover for 24 h, then subjected to
8 μg/ml puromycin selection for 72 h.Fig. 1.Osteopontin (OPN)-expressing hepatic stellate cells (HSC) accumulate in non-alcoholic s
control chow or themethionine choline deﬁcient (MCD) diet for 8 weeks. Livers were harveste
phometry. (C) OPN mRNA; results are expressed as fold change relative to WT control mice. (D
cation ×400); graph shows number of OPN/Desmin double-positive cells per HPF (quantiﬁed b
are graphed as mean ± SEM; *p b 0.05 vs. WT control mice or otherwise indicated.2.7. Transmigration and wound healing assays
For transmigration assays, cells were cultured in the upper chamber
of a 24-well transwell system (3 μmmembrane, Nunc™ Polycarbonate
Membrane Inserts, Thermo Fisher Scientiﬁc, Loughborough, UK). After
24 h, the upper side of the membrane was gently wiped with a cotton
bud to remove non-migrated cells, and the membrane was stained
with crystal violet solution (1% crystal violet, 25% methanol) for
10 min, washed in PBS and allowed to air dry. Cells migrated to the
bottom side of the membrane were visualized on an inverted micro-
scope, and quantiﬁed using the average number of migrated cells per
15 randomly-selected ﬁelds.
Standard wound healing assays were performed by growing cells to
a conﬂuent monolayer, and making a manual scratch using a P200teatohepatitis (NASH) ﬁbrosis. Wild type (WT) and ob/ob (leptin deﬁcient) mice were fed
d for IHC and qRTPCR. Representative staining are shown. (A) OPN staining. (B) OPNmor-
) OPN (brown) and Desmin (marker of HSC) (green)—double immunostaining (magniﬁ-
y cell counting); black arrows indicate cells which co-express OPN and Desmin. All results
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graphed at time 0, and compared 12 h later. Wound diameters were
quantiﬁed using NIH Image J version 1.48v (Rasband, W.S., ImageJ, U.
S. National Institutes of Health, Bethesda, Maryland, USA, http://
imagej.nih.gov/ij/, 1997–2012).
2.8. Semi-quantitative real-time PCR
Total RNAwas extracted from cell cultures using TRIzol® (Life Tech-
nologies, Carlsbad, CA) according to manufacturer's instructions. RNA
(1 μg) was reverse transcribed to cDNA templates using iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA). For semiquantitative RT-PCR,
cDNA (25 ng) was ampliﬁed using SYBR® Green PCR Master Mix (Life
Technologies) and oligonucleotide primers for speciﬁc targets
sequences on an Applied Biosystems 7500 Real-Time PCR system. RT-
PCR parameters were as follows: denaturating at 95 °C for 10 min,Fig. 2.OPN loss abrogates leptinﬁbrogenic effects inHSC. HSC (mouseGRX line)with OPN knoc
for 48 h. Cells were then harvested and RNA analyzed by qRTPCR. (A) OPNmRNA. (B)αSMAm
ative to shScr, and graphed asmean± SEM.Wound-healing and transmigration studies in shOP
migration was quantiﬁed bymeasuring the distance dividing the two sides of themonolayer. M
seeding of cells, by counting crystal violet-stained cells on the undersidemembrane in 15 randofollowed by 40 cycles of denaturing at 95 °C for 15 s and annealing/ex-
tension at 60 °C for 60 s. Threshold cycles (Ct)were automatically calcu-
lated by the system software. Target gene levels were determined
relative to the S9 ribosomal protein housekeeping gene using the
2−ΔΔCt method. Primer sequences are listed in (Supplementary
Table 1).
2.9. Precision cut liver slice organ culture
In order to study the impact of OPN neutralization in the intact liver
we used a Krumdieck Tissue Slicer (TCS Biologicals) to cut aseptic,
250 μm thick slices of live liver tissue, which could be studied for up
to 48 h ex-vivo. Liver tissue was incubated in Williams E media
(Sigma) supplemented with 2% FCS, 0.1 μM dexamethasone (Sigma)
and 0.5 μM insulin (Novo-Nordisk). Tissues were stimulated with
recombinant leptin, in the presence of sham-aptamers or OPN-speciﬁckdown (shOPN) and control HSC (shScr)were treatedwith recombinant leptin (or vehicle)
RNA. (C) Collagen 1α1 mRNA. (D) TGFβmRNA. Results are expressed as fold changes rel-
N or shScr HSCwere performedunder leptin-treated conditions (E-F). (E)Wound healing;
ean (%wound closure)± SEMwere graphed. (F) Transmigration was evaluated 24 h after
mHPF.Mean cell numbers± SEMwere graphed. *p b 0.05 vs shScr or otherwise indicated.
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analysis by real-time PCR. Cell viability was evaluated by measuring
the content of ATP with the ATP Bioluminescence Assay Kit CLS II
(Roche, Basel, Switzerland), normalized against the total amount of
proteins quantiﬁed by Pierce BCA Protein Assay Kit (Thermo Fisher
Scientiﬁc, Waltham, MA). The threshold of viability is 4 nmol/mg pro-
tein of ATP measured 2 h after recovery (i.e. time 0 h in Fig. 5A).
2.10. Statistical analysis
Results are expressed asmeans± SEM. Signiﬁcance was established
using the Student's t-test and analysis of variance. Differences were
considered signiﬁcant when p b 0.05.
3. Results
3.1. Leptin-deﬁcient (ob/ob) livers contain less Osteopontin and are less
ﬁbrotic than control (WT) livers after MCD treatment
Chronic exposure to theMCDdiet induced comparable epithelial cell
injury in WT (leptin-intact) and ob/ob (leptin-deﬁcient) mice [28,29].Fig. 3. OPN is PI3K regulated and enhances ﬁbrogenesis in GRX HSC line. HSC (mouse GRX line
leptin, with or without LY294002 (a PI3K inhibitor). Cells were then harvested and RNA analyze
Results are expressed as fold changes relative to shScr-Leptin, and graphed as mean ± SEM. *pWT mice developed signiﬁcant liver ﬁbrosis in response to the MCD
diet, as evidenced by ~6-fold accumulation of Sirius red stained collagen
ﬁbrils (Suppl Fig. 1A–C), ~2.5-fold increase in hepatic hydroxyproline
content (Suppl Fig. 1D), and a 4-fold upregulation in collagen 1α1
mRNA (Suppl Fig. 1E). Collagen depositionwas accompanied by the accu-
mulation ofαSMA+ cells (Suppl Fig. 2A–B), OPN+ cells (Fig. 1A–B), and
induction of key ﬁbrogenic genes, αSMA (~4-fold) (Suppl Fig. 2C), TGF-
β1 (~3-fold) (Suppl Fig. 2D), and OPN (greater than 10-fold) (Fig. 1C).
By contrast, ﬁbrosis was signiﬁcantly less in ob/ob mouse livers after
theMCDdiet (Suppl Fig. 1): ob/ob livers containednearly 50% fewer Sirius
red stained collagen ﬁbrils (Suppl Fig. 1A–C), ~2.5-fold less liver hydroxy-
proline (Suppl Fig. 1D), ~50% less TGF-β1 mRNA, and exhibited minimal
induction of collagen 1α1, αSMA and OPN mRNA (Suppl Fig. 1E, 2C, 2D,
and Fig. 1C). The degree of weight loss however, was similar between
(WT and ob/ob) MCD-fed groups. These ﬁndings conﬁrm that leptin di-
rectly promotes ﬁbrogenesis in MCD-induced NASH [11,19,28].
3.2. OPN is a downstream effector of Leptin in Hepatic Stellate Cells (HSC)
Leptin is a pro-ﬁbrogenic adipokinewhichdirectly activates HSC, the
liver pericyte responsible for collagen matrix deposition during chronic) with OPN knockdown (shOPN) and control HSC (shScr) were treated with recombinant
d by qRTPCR. (A) OPNmRNA. (B)αSMAmRNA. (C) Collagen 1α1mRNA. (D) TGFβmRNA.
b 0.05 vs. shScr-Leptin.
Fig. 4. OPN is a downstream target of leptin and is PI3K/Akt regulated in primary HSC.
Freshly isolated HSC were treated with leptin (or vehicle), with or without LY294002.
Additional HSC were also pre-treated with Ad5dnAkt (or Ad5GFP) prior to treatment
with leptin (100 ng/ml) or Ad5mryAkt alone. RNA was isolated and changes in gene
expression evaluated by qRT-PCR. (A) OPN mRNA. (B) αSMA mRNA. (C) Collagen 1α1
mRNA. Results are expressed as fold changes relative to vehicle-treated HSC, and graphed
as mean ± SEM. *p b 0.05 vs. vehicle.
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cytokine, could also promote HSC activation [23,24]. In this study, the
loss of circulating leptin was directly associated with repressed liver
OPN (Fig. 1), and attenuated liver ﬁbrogenesis (Suppl Fig. 1, 2). These
observations led us to hypothesize that leptin could regulate OPN ex-
pression in HSC.
Recent studies revealed that HSC isolated from livers subjected to
biliary or chemical injury upregulated OPN mRNA (Suppl Fig. 3) [30].
In support, we conﬁrmed by double immunohistochemistry that des-
min (+) HSC co-expressed OPN (Fig. 1D). Importantly, the number of
desmin/OPN double (+) HSC accumulated by more than 5-fold in
MCD-fed mice, but this increase was almost abolished in ob/ob-MCD
mice.
To determine if leptin was directly inﬂuencing OPN expression in
HSC, we treated the mouse HSC line, GRX, with recombinant leptin
(rleptin) for 48 h; cellswere then harvested for RNA analysis by qRTPCR.
rLeptin activated HSC (Suppl Fig. 4), upregulated OPN, and key
ﬁbrogenic markers, αSMA, collagen 1α1, TGFβ (~2-fold) (Fig. 2A–D).
We next investigated if loss of OPN would inhibit leptin ﬁbrogenic
effects. To this end, GRX were treated with lentiviral particles which
contain shRNA constructs speciﬁcally targeting OPN (GRX-shOPN).
Comparedwith control (GRX-shScr) (GRX infectedwith lentiviral parti-
cles containing non-targeting scrambled shRNA), OPN knockdown
(~80%) (Suppl Fig. 5) signiﬁcantly abrogated leptin ﬁbrogenic effects
by N90% (Fig. 2). As increased cell migration is an important feature of
activated HSC, we further examined if OPN knockdown (under leptin-
stimulated conditions) would impair HSC migratory properties.
Migration was assessed by semi-quantitating the dimensions of a
wound dividing the conﬂuent monolayer 12 h after the scratch. OPN
knockdown led to ~15% less wound healing compared with controls
(p b 0.05) (Fig. 2E). Comparable results observed in the modiﬁed cell-
invasion assay (Fig. 2F). OPN knockdown led to 50% fewer GRX cells
invading across the insert membrane.
We veriﬁed these results using OPN-speciﬁc aptamers which
neutralize circulating OPN [25,26], in the presence of rleptin. OPN neu-
tralization blunted αSMA expression (Suppl Fig. 6A), and signiﬁcantly
repressed collagen 1α1 and TGFβ mRNA (~50%) (Suppl Fig. 6B–C).
Similar to knockdown experiments, OPN neutralization also inhibited
migratory properties of HSC, leading to impaired wound healing
(~30%) and transmigration (~50%) across membranes (Suppl Fig. 6D–
E). In aggregate, these results demonstrate that OPN is a downstream
effector of leptin-induced ﬁbrogenesis, and that OPN is a potential
anti-ﬁbrotic target.
3.3. OPN expression is regulated by Leptin-PI3K/Akt signaling in HSC
Leptin receptors couple with PI3K and activate Akt, which is
required for leptin-associated ﬁbrogenic effects [31,32]. Leptin
activates the hedgehog (Hh) pathway (an important morphogenic
pathway during development and adult ﬁbrogenesis) in HSC, but
this is blocked by LY294002, a PI3K inhibitor [19]. Because OPN is a
downstream target of the Hh pathway [24], we investigated if OPN
could similarly be regulated by the PI3K/Akt pathway. GRX HSCs
were treated with leptin in the presence or absence of LY294002.
LY294002 signiﬁcantly repressed OPN mRNA by N50% (Fig. 3A),
and downregulated ﬁbrogenic genes αSMA, collagen 1α1, and
TGFβ by up to 60% (Fig. 3B–D). OPN knockdown in combination
with LY294002 further enhanced repression of ﬁbrogenic genes by
an additional ~20% (Fig. 3).
To exclude the possibility that observed responses were GRX-
speciﬁc, we repeated experiments using freshly isolated rat HSC.
Comparable with GRX HSCs, leptin-treated, primary rat HSC upregulat-
ed OPN,αSMA, and collagen 1α1mRNA by ~2-fold (Fig. 4A–C), but this
effect was completely blocked in the presence of LY294002. OPNmRNA
in particular, was repressed below basal expression. Adenoviral-
mediated transfer of dominant negative Akt (dnAkt) similarly inhibitedleptin-mediated changes in OPN, αSMA, and collagen 1α1 mRNA (Fig.
4A–C), but infection with mock adenoviral vectors (AdGFP; control)
did not. By contrast, infection with the constitutively active Akt vector
(Ad5myrAkt) induced OPN, αSMA, and collagen 1α1 mRNA to levels
comparable with leptin-treated cells (Fig. 4).
Previous studies suggested that leptin-mediated induction of the
JAK/STAT pathway inﬂuences HSC ﬁbrogenesis [11,23]. To clarify the
role of leptin-mediated JAK/STAT signaling in modulating OPN
expression, primary rat HSC were also treated with leptin in the pres-
ence or absence of AG490 (an inhibitor of JAK signaling). Compared
with DMSO control, pre-treatment with AG490 inhibited OPN mRNA
by ~30%.However this effect was signiﬁcantly less pronounced than
LY294002 treatment (Suppl Fig. 7). These data in aggregate conﬁrm
that OPN expression in HSC is predominantly leptin-PI3K/Akt-
regulated.
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cut liver slices (PCLS) and in a mouse model of diet-induced NASH
To validate in vitro ﬁndings, we used an established liver organ
culture system in which precision-cut, viable mouse liver slices (PCLS)
were stimulated with leptin, in the presence of sham- or OPN-speciﬁc
aptamers. PCLS are useful because they can be cultured for several
days and better reﬂect the multicellular in vivo conditions [33,34].
Liver slice viability was maintained as evidenced by the MTT assay
(Fig. 5A). Treatment with exogenous leptin upregulated liver slices
OPN mRNA by ~2-folds (Fig. 5B), and induced αSMA and collagen
1α1mRNA by ~20% (Fig. 5C–D). Conversely, neutralizing OPN signiﬁ-
cantly repressed OPN and collagen 1α1mRNA, even beyondbasal levels.
No change in total slice αSMA mRNA was detected.
Having demonstrated that OPN is the downstream, ﬁbrogenic
effector of leptin, we evaluated the impact of OPN neutralization inFig. 5. OPN neutralization abrogates ﬁbrogenesis in precision-cut liver slices (PCLS). Precision-
leptin (or vehicle), in the presence of sham- or OPN-speciﬁc aptamers for 48 h. At the end of tr
by qRTPCR. (A) ATP content (viability) in nmol/mg protein; hashed line denotes the accepted v
expressed as fold changes relative to vehicle-treated PCLS, and graphed as mean ± SEM. *p b 0MCD-fed, leptin-intact (i.e.WT)mice.MCD-fedmicewere administered
sham-aptamers or OPN-speciﬁc aptamers via tail-vein for 2 weeks. At
the end of treatment, livers were harvested and ﬁbrosis was assessed
by qRTPCR and IHC. As expected, mice developed NASH-ﬁbrosis
after 5 weeks of the MCD diet (Fig. 6 and Suppl Fig. 1A) [23,24]. Consis-
tentwith cell culture and PCLSﬁndings, OPN neutralization signiﬁcantly
reduced MCD diet-induced ﬁbrosis, as evidenced by fewer Sirius-Red
stained collagen ﬁbrils (Fig. 6A–B), attenuated expression of ﬁbrogenic
genes, αSMA, collagen 1α1 (Fig. 6C–D), and reduced liver OPN
expression (Fig. 6E–F).
4. Discussion
Our study conﬁrms that OPN is a key driver of HSC activation, and is
an important downstream effector of leptin-induced ﬁbrogenesis. Loss
of OPN using OPN-speciﬁc aptamers or OPN knockdown abrogatescut, viable mouse liver slices (PCLS) (a liver organ culture system) were stimulated with
eatment, liver slices were harvested, viability assessed by ATP content, and RNA analyzed
iability threshold. (B) OPN mRNA. (C) αSMA mRNA. (D) Collagen 1α1 mRNA. Results are
.05 vs. vehicle.
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in vitro observations were recapitulated in the ex vivo liver slice
model. Importantly, OPN neutralization in a mouse model of diet-
induced NASH signiﬁcantly reduced liver ﬁbrosis, thereby reinforcing
the potential utility of targeting OPN in the treatment of patients with
advanced stage NASH.
These results are consistent with ﬁndings from studies on Hh
signaling in liver ﬁbrosis. Both OPN and Hh are leptin-regulated, and
are key effectors of leptin-induced liver ﬁbrosis. Although the Hh path-
way is recognized for its role in embryonic development, recent studies
also show that it regulates adult tissue repair [35]. An over-activation of
the Hh pathway leads to tissue ﬁbrosis and cancer, while the loss of Hh
signaling impairswoundhealing (i.e. lessﬁbrosis) [5,36]. In the liver, weFig. 6.OPN neutralization inhibits diet-induced NASH ﬁbrosis in leptin-intactmice. Leptin-intac
OPN-aptamers. Mice were sacriﬁced 24 h after ﬁnal dose of aptamers, and livers analyzed. (A)
shows Sirius-red staining from a control-fed mouse. (B) Sirius-red morphometry. (C) Collage
aptamer treated mice, and graphed as mean ± SEM. *p b 0.05 vs. sham-aptamer treated mice.
OPN staining from control-fed mouse. (F) OPN morphometry.and others recently reported that over-activation of the Hh pathway
occurs during human NASH progression [37,38], and that blocking Hh
with the commercially available inhibitor, GDC0449 or cyclopamine
ameliorates NASH and reduces liver ﬁbrosis in mice [37,38].
The role of OPN in liver inﬂammation and ﬁbrosis is complex, and
has only begun to be unravelled. Outside of the liver, OPN appears to
exhibit fairly divergent roles in acute and chronic diseases. In allergic
airway disease, OPN is pro-inﬂammatory during primary systemic
sensitization, but anti-inﬂammatory during secondary antigenic
challenge [39]. Similarly, in the lpr model (autoimmune disease that
resembles systemic lupus erythematosus), OPN mediates pathology in
early disease, but limits exacerbation in late stage disease [40]. In the
liver, cumulative evidence suggest that targeting OPN early in diseaset (WT)micewere fed control chowor theMCDdiet for 6weeks, in the presence of shamor
Representative Sirius-red staining; black arrows indicate Sirius-red stained ﬁbrils. Insert
n 1α1 mRNA. (D) αSMA mRNA. Results are expressed as fold changes relative to sham-
(E) Representative OPN staining; black arrows indicated OPN-positive cells. Insert shows
143J.D. Coombes et al. / Biochimica et Biophysica Acta 1862 (2016) 135–144(i.e. prevention) may result in worsening outcomes [41]. On the other
hand, the current data conﬁrms that neutralizing OPN in advanced
stage liver disease is beneﬁcial, as demonstrated by the reduced ﬁbrosis
in an established model of NASH ﬁbrosis.
The prevalence of NAFLD and NASH is increasing in parallel with the
rising tide of obesity and type 2 diabetes mellitus. Studies show that
obese individuals and those who harbour additional metabolic risk
factors are at a much higher risk of developing NASH and/or NASH-
ﬁbrosis [42,43]. Therefore, targeting ‘modiﬁable’ mediators in these
‘at-risk’ individuals could help alleviate NASH/ﬁbrosis burden. Leptin
is an adipose tissue-derived hormone whose physiological role is to
induce satiety, but levels of leptin are signiﬁcantly higher in the obese,
and in somewithNAFLD [16,17]. To date, studies have evaluated the po-
tential utility of leptin replacement in those with hypoleptinemia-
NASH. In one study, leptin administration improved steatosis, but not
ﬁbrosis stage [44], and as leptin is directly pro-ﬁbrogenic, it is possible
that supplementation of exogenous leptin may inadvertently lead to
worsening ﬁbrosis. On the other hand, leptin-neutralization in those
with advanced NASH-ﬁbrosis (and excess leptin) may be a useful anti-
ﬁbrotic strategy (as observed in our study), although the likely increase
in food intake and body weight (and metabolic risk) may well cancel
out any potential clinical beneﬁt.
Like leptin, plasma OPN levels are increased in the obese and in
patients with type 2 diabetes mellitus, hypertension, and ischemic
heart disease [45]. More recently, serumOPNwas also found to be asso-
ciated with the onset of diabetic nephropathy and cardiac events [46].
Thus, high levels of OPN occur in those with the metabolic syndrome,
a risk factor for progressive NASH. Importantly, OPN neutralization
reduces inﬁltration of macrophages and immune subsets into adipose
tissues, reduces obesity-induced inﬂammation, and improves systemic
glucose tolerance [47–50]. In concert with the current ﬁndings, these
data suggest that OPN could be an important target in the treatment
of obese patients with NASH (and the metabolic syndrome), by reduc-
ing insulin resistance and limiting NASH-ﬁbrosis (in spite of high
prevailing leptin levels).
In summary, our analyses in cell-culture and mice show that OPN is
leptin-regulated, and is a key effector of leptin-induced, NASH-ﬁbrosis.
Future studies will be necessary to evaluate the utility of OPN neutrali-
zation in a different model of obesogenic NASH (such as the high-fat,
high fructose/sucrose-fed model), and evaluate if extended periods of
treatment could lead to even better anti-ﬁbrotic outcomes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.10.028.
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